MAP2K7 and melanoma: The MEK inhibitors PD0325901 and AZD6244 have also been evaluated in early clinical trials, however, without improvement in the progression-free survival compared to Temozolomide [6], an oral form of the chemotherapeutic drug Dacarbazine used to treat melanoma patients.